| Net income | |
| Depreciation and amortization | 160.7M |
| Purchased research and development | |
| Restructuring | |
| Legal settlements and commitments | |
| Deferred income taxes | -42.8M |
| Share-based compensation | 68.3M |
| Inventory reserves and provision for doubtful accounts | 23.3M |
| Other noncash items | 2.1M |
| Accounts receivable | 10.3M |
| Inventories | -78.7M |
| Current liabilities | |
| Taxes | -19.5M |
| Other, net | -5.1M |
| Net cash provided by operating activities | |
| Capital expenditures | -64.6M |
| Change in short term investments, net | |
| Payments made for purchases of businesses, net of cash acquired | -202.8M |
| Payments made for intangibles | -600K |
| Net cash used in investing activities | |
| Change in short-term borrowings, net | 0 |
| Purchase of noncontrolling interest | |
| Proceeds from exercises under share-based compensation plans, net | |
| Excess tax benefit relating to share-based compensation plans | 35.3M |
| Purchase of common stock | -231.8M |
| Dividends paid | -55.3M |
| Other | |
| Net cash used in financing activities | |
| Effect of exchange rate changes on cash and cash equivalents | 900K |
| Increase (decrease) in cash and cash equivalents during the period | 45.9M |
| Balance at January 1 | 950.5M |
| Balance at June 30 | 996.4M |
| Interest | 37.1M |
| Income taxes | |
| Purchase of business and related costs | |
| Dividends declared, not paid | |
| Receipt of foreign government bonds | |